To this aim, the same number of AML blasts (30,000 WT or Selplg–/– BM KIT+GFP+ cells) were transplanted into wildtype mice on the same day, but cytarabine treatment started 3 weeks post-transplant for mice recipients of WT AML and at 12 weeks post-transplant in mice that received Selplg–/– AML (Figure 5A). The gene discussed is SELPLG; the disease is acute myeloid leukemia.